

**ProteoTech to Present at
The 5th Neurodegenerative Conditions Research and Development Conference
San Francisco, California, September 22-23, 2011**

Kirkland, WA, September 22, 2011 – ProteoTech, Inc. announced today that Dr. Luke Esposito, Director of Neuroscience Research, will present at The 5th Neurodegenerative Conditions Research and Development Conference to be held in San Francisco, California, September 22-23, 2011.

Dr. Esposito will present on Friday, September 23 during the “Protein Misfolding and Aggregation” Symposium. Dr. Esposito’s presentation is entitled:

“SynuclereTM: A Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction as a Potential Parkinson’s disease-Modifying Therapeutic.”

SynuclereTM is a novel small molecule developed by ProteoTech that is postulated to be a disease-modifying treatment for Parkinson’s disease and related disorders.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides *SynuclereTM* in late stage pre-clinical development for the treatment of Parkinson's disease, the Company is developing EXEBRYL-1® for the treatment of Alzheimer's disease, SystebrylTM for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called **PeptiClereTM** for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.